Nyrada Inc. (NYR.AX)
AUD 0.11
(0.0%)
AUD 0.11
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 5.9 Million AUD | 14.38% |
| 2023 | 5.16 Million AUD | -57.01% |
| 2022 | 12.01 Million AUD | -20.73% |
| 2021 | 15.15 Million AUD | 141.84% |
| 2020 | 6.26 Million AUD | 448.25% |
| 2019 | 1.14 Million AUD | -63.94% |
| 2018 | 3.17 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 FY | 5.9 Million AUD | 14.38% |
| 2024 Q4 | 5.9 Million AUD | 0.0% |
| 2024 Q2 | 5.06 Million AUD | 0.0% |
| 2023 Q2 | 10.4 Million AUD | 0.0% |
| 2023 FY | 5.16 Million AUD | -57.01% |
| 2023 Q4 | 5.16 Million AUD | 0.0% |
| 2022 Q4 | 12.01 Million AUD | 0.0% |
| 2022 Q2 | 12.72 Million AUD | 0.0% |
| 2022 FY | 12.01 Million AUD | -20.73% |
| 2021 FY | 15.15 Million AUD | 141.84% |
| 2021 Q4 | 15.15 Million AUD | 0.0% |
| 2021 Q2 | 4.13 Million AUD | 0.0% |
| 2020 Q4 | 6.26 Million AUD | 0.0% |
| 2020 FY | 6.26 Million AUD | 448.25% |
| 2020 Q2 | 851.26 Thousand AUD | 0.0% |
| 2019 FY | 1.14 Million AUD | -63.94% |
| 2019 Q4 | 1.14 Million AUD | 0.0% |
| 2019 Q1 | - AUD | 0.0% |
| 2018 FY | 3.17 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AdAlta Limited | 5.57 Million AUD | -5.998% |
| Acrux Limited | 8.96 Million AUD | 34.093% |
| Amplia Therapeutics Limited | 14.84 Million AUD | 60.207% |
| Biome Australia Limited | 8.27 Million AUD | 28.629% |
| BTC Health Limited | 5.14 Million AUD | -14.731% |
| Chimeric Therapeutics Limited | 15.27 Million AUD | 61.323% |
| CSL Limited | 56.93 Billion AUD | 99.99% |
| Clarity Pharmaceuticals Ltd | 154.62 Million AUD | 96.18% |
| Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | 97.444% |
| Noxopharm Limited | 6.78 Million AUD | 12.92% |
| PharmAust Limited | 11.12 Million AUD | 46.9% |
| Proteomics International Laboratories Limited | 10.87 Million AUD | 45.681% |
| Prescient Therapeutics Limited | 20.39 Million AUD | 71.033% |
| PYC Therapeutics Limited | 91.23 Million AUD | 93.525% |
| Race Oncology Limited | 20.22 Million AUD | 70.797% |
| Starpharma Holdings Limited | 36.81 Million AUD | 83.954% |
| EZZ Life Science Holdings Limited | 25.55 Million AUD | 76.881% |
| Botanix Pharmaceuticals Limited | 112.46 Million AUD | 94.747% |
| Memphasys Limited | 12.43 Million AUD | 52.476% |
| Anatara Lifesciences Ltd | 1.67 Million AUD | -253.427% |
| Telix Pharmaceuticals Limited | 398.3 Million AUD | 98.517% |
| Bio-Gene Technology Limited | 3.15 Million AUD | -86.963% |
| Zelira Therapeutics Limited | 5.18 Million AUD | -13.965% |
| Patrys Limited | 4.16 Million AUD | -41.948% |
| Dimerix Limited | 32.07 Million AUD | 81.585% |
| Neuren Pharmaceuticals Limited | 247.97 Million AUD | 97.618% |
| Orthocell Limited | 26.61 Million AUD | 77.805% |
| Imugene Limited | 151.39 Million AUD | 96.098% |
| Cynata Therapeutics Limited | 8.38 Million AUD | 29.577% |
| Immutep Limited | 147.44 Million AUD | 95.994% |
| Arovella Therapeutics Limited | 13.28 Million AUD | 55.533% |
| Alterity Therapeutics Limited | 19.22 Million AUD | 69.271% |
| Nanollose Limited | 241.95 Thousand AUD | -2341.512% |
| Invex Therapeutics Ltd | 6.12 Million AUD | 3.477% |
| NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | -8.672% |
| Island Pharmaceuticals Limited | 2.56 Million AUD | -130.35% |
| Biotron Limited | 493.47 Thousand AUD | -1097.072% |
| Radiopharm Theranostics Limited | 72.03 Million AUD | 91.8% |
| Tissue Repair Ltd | 19.38 Million AUD | 69.534% |
| AnteoTech Limited | 9.38 Million AUD | 37.031% |
| Hexima Limited | 2.26 Million AUD | -160.346% |
| Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | 78.433% |
| Recce Pharmaceuticals Ltd | 6.36 Million AUD | 7.259% |
| Avecho Biotechnology Limited | 7.31 Million AUD | 19.292% |
| Actinogen Medical Limited | 21.31 Million AUD | 72.282% |
| Immuron Limited | 15.54 Million AUD | 62.011% |
| Argenica Therapeutics Limited | 16.37 Million AUD | 63.931% |